News
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...
US-Unternehmen werden an der Börse höher bewertet als europäische. Das schreckt mittlerweile viele Investoren ab. Allerdings gibt es Ausnahmen, auf die auch institutionelle Anleger setzen.
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream NBC 5 for free, 24/7, wherever you are. The Danish drugmaker on Friday ...
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream San Diego News for free, 24/7, wherever you are with NBC 7. The Danish ...
WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from US rival Eli Lilly, makes inroads into its market share and as its pipeline of new ...
Wie die Skandinavier mitteilten, gibt der bisherige Chef Lars Fruergaard Jorgensen seinen Posten nach acht Jahren an ... Konkurrenz durch den US-Konzern Eli Lilly setzte das Unternehmen aber ...
The pharmaceutical giant has been racing against rivals such as Eli Lilly to dominate the highly lucrative weight-loss space. Morgan Stanley Research is projecting that the global market for ...
Eli Lilly's potential Houston expansion could bring thousands of jobs and billions of dollars in investment to the area. Here's where the plant might be built ...
Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback